A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

被引:28
|
作者
Chida, M
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam,Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
[4] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*18; genotype;
D O I
10.1097/00008571-199906000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Two poor metabolizer individuals of debrisoquine were identified among 215 healthy Japanese by a phenotyping test, Analysis of the CYP2D6 gene from one of two poor metabolizers, who was not homozygous for the previously described CYP2D6 Variant alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*18), showed that this individual was heterozygous for a new allele, CYP2D6/C8 (CYP2D6*21), CYP2D6*21 I had a single cytosine insertion at position 2661 in exon 5, This cytosine insertion generated a stop codon at the 17 bp downstream of this insertion site, A method to detect this allele was established with an allele specific-polymerase chain reaction, This method showed that another one of two poor metabolizers also possessed CYP2D6*21 allele heterozygously, In 318 healthy Japanese, five individuals carried this allele, heterozygously (0.81%, 5/636 chromosomes), Based on the present and our previous data, the poor metabolizer frequency in Japanese was estimated to be 0.39%, which accounted for approximately 45% of the individuals phenotyped as poor metabolizers by in-vivo tests. Pharmacogenetics 9:287-293 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 50 条
  • [21] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation
    de Leon, J
    Susce, MT
    Pan, RM
    Fairchild, M
    Koch, WH
    Wedlund, PJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) : 15 - 27
  • [22] EVIDENCE FOR A NEW VARIANT CYP2D6 ALLELE CYP2D6J IN A JAPANESE POPULATION ASSOCIATED WITH LOWER IN-VIVO RATES OF SPARTEINE METABOLISM
    YOKOTA, H
    TAMURA, S
    FURUYA, H
    KIMURA, S
    WATANABE, M
    KANAZAWA, I
    KONDO, I
    GONZALEZ, FJ
    PHARMACOGENETICS, 1993, 3 (05): : 256 - 263
  • [23] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [24] IDENTIFICATION OF A NEW VARIANT CYP2D6 ALLELE LACKING THE CODON ENCODING LYS-281 - POSSIBLE ASSOCIATION WITH THE POOR METABOLIZER PHENOTYPE
    TYNDALE, R
    AOYAMA, T
    BROLY, F
    MATSUNAGA, T
    INABA, T
    KALOW, W
    GELBOIN, HV
    MEYER, UA
    GONZALEZ, FJ
    PHARMACOGENETICS, 1991, 1 (01): : 26 - 32
  • [25] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [27] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [28] Genetic polymorphism of CYP2D6 in the Japanese population
    Chida, M
    Yokoi, T
    Kosaka, Y
    Chiba, K
    Nakamura, H
    Ishizaki, T
    Yokota, J
    Kinoshita, M
    Sato, K
    Inaba, M
    Aoki, Y
    Gonzalez, FJ
    Kamataki, T
    PHARMACOGENETICS, 1999, 9 (05): : 601 - 605
  • [29] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [30] Endoxifen Levels Associated to CYP2D6 Phenotype
    Antunes, M., V
    Santos, T., V
    Andreolla, H.
    Rosa, D. D.
    Linden, R.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 710 - 710